Transplantation

1.    MacEwan DJ. TNF ligands and receptors--a matter of life and death. Br J Pharmacol 2002;135:855-75.
2.    Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2.
3.    Tangye SG et al. Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol 2007;179:13-9.
4.    Kara IO et al. Levels of serum and cerebrospinal fluid soluble CD27 in the diagnosis of leptomeningeal involvement of hematolymphoid malignancies. Adv Ther 2007;24:741-7.
5.    Widney D et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114-23.
6.    Hintzen RQ et al. Cerebrospinal fluid concentrations of soluble CD27 in HTLV-I associated myelopathy and multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;66:791-3.
7.    Bohnhorst JØ et al. Abnormal B cell differentiation in primary Sjögren's syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol 2002;103:79-88.
8.    Kallio P et al. Soluble CD27 in thyroid disorders. J Lab Clin Med 1998;132:478-82.
9.    Schlaf G et al. Soluble CD30 serum level –an adequate marker for allograft rejection of solid organs? Histol Histopathol 2007;22:1269-79.
10.    Diegmann J et al. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 2006;8:933-8.
11.    Georgopoulos NT et al. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006;13:1789-801.
12.    Lane P et al. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993;177:1209-13.
13.    Durie FH et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261:1328-30.
14.    Boyce BF et al. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9 Suppl 1:S1.
15.    Maury CP. Interleukin 1 and the pathogenesis of inflammatory diseases. Acta Med Scand 1986;220:291-4.
16.    Chin JE et al. Role of cytokines in inflammatory synovitis. The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts. Arthritis Rheum 1990;33:1776-86.
17.    Alvaro-Gracia JM et al. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990;86:1790-8.
18.    Waage A et al. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987;1:355-7.
19.    Osuchowski MF et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006;177:1967-74.
20.    Calabrese F et al. Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol 2004;17:1108-18.
21.    Spies T et al. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci 1986;83:8699-8702.
22.    Broudy VC et al. Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells. J Immunol 1987;138:4298-4302.
23.    Shalaby MR et al. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 1985;135:2069-73.
24.     Locksley RM et al. Tumor necrosis factors alpha and beta differ in their capacities to generate interleukin 1 release from human endothelial cells. J Immunol 1987;139:1891-5.
25.    Heilig B et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993;13:321-8.
26.    Gruss HJ et al. The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia 1993;7:1339-43.
27.    Herbein G et al. Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol 2008;29:61-7.
28.    Maher B et al. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters. Antivir Ther 2004;9:879-87.
29.    Zheng TS et al. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. J Leukoc Biol 2008. (Epub ahead of print).
30.    Park MC et al. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008;37:173-8.
31.    Sanz AB et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008;19:695-703.
32.    Zhao Z et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007;179:7949-58.
33.    Burkly LC et al. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40:1-16.
34.    Schwartz N et al. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 2007;1109:265-74.
35.    Winkles JA et al. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007;12:2761-71.
36.    Nagasawa M et al. Soluble TWEAK is markedly elevated in hemophagocytic lymphohistiocytosis. Am J Hematol 2008;83:222-5.
37.    Bosello S et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 2007;20:1-8.
38.     Reyes S LI et al. BAFF: A regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer. Rev Med Chil 2006;134:1175-84.
39.    Mackay F et al. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006;18:284-9.
40.    Ng LG et al. The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 2005;42:763-72.
41.    Rizvi M et al. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med. 2008;14:530-8.
42.    Contin C et al. Immune dysfuntion of uremic patients: potential role for the soluble form of CD40. Nephrologie 2004;25:119-26.
43.    Johnstone RW et al. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98.
44.    Mueller AM et al. The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol 2009. [Epub ahead of print]
45.    Hayashi S et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007;56:1067-75.
46.    Kim S et al. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 2004;72:89-93.
47.    Yang CR et al. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 2004;11 Suppl 1:S97-107.
48.    So T et al. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 2008;19:253-62.
49.    Redmond WL et al. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 2007;27:415-36.
50.    Scholl N et al. The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders. Leuk Lymphoma 2009;50:427-36.
51.    Liu GZ et al. Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis. Scand J Immunol 2006;64:412-9.
52.    Jung HW et al. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2004;36:13-22.
53.    Kamihira S et al. Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia. Leuk Lymphoma 2001;41:169-76.
54.    Tohyama M et al. A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome. Br J Dermatol 2008;159:981-4.